Pyrazines, pyrimidines and pyridazines useful in the treatment of senile
申请人:Merck Sharp & Dohme Limited
公开号:US05260293A1
公开(公告)日:1993-11-09
The present invention provides pyrazines, pyridazines or pyrimidines, or salts or prodrugs thereof, substituted on one of the ring carbon atoms thereof with a non-aromatic azacyclic or azabicyclic ring system; and independently substituted on each of the other ring carbon atoms with a substituent of low lipophilicity or a hydrocarbon substituent; which compounds stimulate central muscarinic acetylcholine receptors and therefore are useful in the treatment of neurological and mental illnesses.
Substituted pyrazines, pyrimidines and pyridazines for use in the
申请人:Merck Sharp & Dohme
公开号:US05219849A1
公开(公告)日:1993-06-15
A class of pyrazine, pyrimidine and pyridazine derivatives, substituted by a non-aromatic azabicyclic ring system and optionally by up to two further substituents, is of use in the preparation of medicaments, especially formulations adapted for topical administration to the eye, suitable for the treatment of glaucoma and/or for reducing intraocular pressure.
Synthesis and muscarinic activity of quinuclidinyl- and (1-azanorbornyl)pyrazine derivatives
作者:Leslie J. Street、Raymond Baker、Tracey Book、Austin J. Reeve、John Saunders、Timothy Willson、Rosemarie S. Marwood、Shailendra Patel、Stephen B. Freedman
DOI:10.1021/jm00080a014
日期:1992.1
been explored. Optimal muscarinic agonist activity was observed for unsubstituted pyrazines in the azanorbornane series. The exo-1-azanorbornane 18a is one of the most efficacious and potent centrally active muscarinic agonists known. Studies on the 3-substituted derivatives have provided evidence of the preferred conformation of these ligands for optimal muscarinicactivity. Substitution at C6 gave